Cargando…

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of drugs with potent glucose-lowering activity. Additionally, some GLP-1 RAs have demonstrated cardiovascular and renal benefits. Current guidelines recommend their use in patients with type 2 diabetes (T2D) at high risk of or with es...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romera, Irene, Rubio-de Santos, Miriam, Artola, Sara, Suárez Fernández, Carmen, Conget, Ignacio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070220/ https://www.ncbi.nlm.nih.gov/pubmed/36821026 http://dx.doi.org/10.1007/s12325-023-02442-z

Ejemplares similares

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain
por: Conget, Ignacio, et al.
Publicado: (2016)

Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes
por: Vázquez, Luis Alberto, et al.
Publicado: (2023)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Real-Life Management and Effectiveness of Insulin Pump with or Without Continuous Glucose Monitoring in Adults with Type 1 Diabetes
por: Viñals, Clara, et al.
Publicado: (2019)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
por: Menghini, Rossella, et al.
Publicado: (2023)

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
por: Norrbacka, Kirsi, et al.
Publicado: (2021)

The impact of strict COVID-19 lockdown in Spain on glycemic profiles in patients with type 1 Diabetes prone to hypoglycemia using standalone continuous glucose monitoring
por: Mesa, Alex, et al.
Publicado: (2020)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
por: Blonde, Lawrence, et al.
Publicado: (2018)

Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains
por: Augsten, Martin, et al.
Publicado: (2014)

Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain
por: Rubio de Santos, Miriam, et al.
Publicado: (2022)

Regulation of Ras Exchange Factors and Cellular Localization of Ras Activation by Lipid Messengers in T Cells
por: Jun, Jesse E., et al.
Publicado: (2013)

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
por: Imam, Ahmad, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
por: Geloneze, Bruno, et al.
Publicado: (2017)

Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
por: Hu, Ying, et al.
Publicado: (2022)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
por: Uzoigwe, Chioma, et al.
Publicado: (2021)

Physical activity patterns in type 1 diabetes in Spain: The SED1 study
por: Gómez-Peralta, F, et al.
Publicado: (2023)

Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review
por: Watkins, Jonathan D, et al.
Publicado: (2021)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
por: Xu, Dan, et al.
Publicado: (2022)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

The efficacy of GLP‐1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review
por: Llewellyn, David C., et al.
Publicado: (2022)

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2018)

PSUN276 GLP1RAs use for treating NALFD in a multidisciplinary clinic in low socioeconomic community
por: West, Brittany, et al.
Publicado: (2022)

Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review
por: Artime, Esther, et al.
Publicado: (2021)

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2019)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
por: Petrovic, Ana, et al.
Publicado: (2023)

FRI639 Effect Of Early Initiation Of GLP-1 RAs On Weight Reduction Among People With Type 2 Diabetes
por: Chinthammit, Chanadda, et al.
Publicado: (2023)

GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
por: Heidarzadeh, Sara, et al.
Publicado: (2013)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study
por: Greco, Salvatore, et al.
Publicado: (2023)

Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

Glucose Control and Cardiovascular Disease: Is it important? No
por: Conget, Ignacio, et al.
Publicado: (2009)

Comment on: Gruden et al. Severe Hypoglycemia and Cardiovascular Disease Incidence in Type 1 Diabetes: The EURODIAB Prospective Complications Study. Diabetes Care 2012;35:1598–1604
por: Giménez, Marga, et al.
Publicado: (2012)

Changes in the Epidemiology of Diabetic Retinopathy in Spain: A Systematic Review and Meta-Analysis
por: Romero-Aroca, Pedro, et al.
Publicado: (2022)

How much does a forensic autopsy cost in Spain?
por: Martín-Cazorla, Fernando, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rdmeroglfr8mclgeopqfrjti7g